Cellumed Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 12:02 am
Share
Cellumed Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 78.6 million compared to KRW 99.38 million a year ago. Net loss was KRW 1,280.74 million compared to KRW 1,007.34 million a year ago. Basic loss per share from continuing operations was KRW 30 compared to KRW 22 a year ago. Diluted loss per share from continuing operations was KRW 30 compared to KRW 22 a year ago. Basic loss per share was KRW 30 compared to KRW 25 a year ago. Diluted loss per share was KRW 30 compared to KRW 25 a year ago.
For the nine months, sales was KRW 180.74 million compared to KRW 296.63 million a year ago. Net loss was KRW 12,664.36 million compared to net income of KRW 1,864.14 million a year ago. Basic loss per share from continuing operations was KRW 298 compared to basic earnings per share from continuing operations of KRW 52 a year ago. Diluted loss per share from continuing operations was KRW 298 compared to diluted earnings per share from continuing operations of KRW 51 a year ago. Basic loss per share was KRW 298 compared to basic earnings per share of KRW 47 a year ago. Diluted loss per share was KRW 298 compared to diluted earnings per share of KRW 46 a year ago.
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
CELLUMED CO.,LTD. 
